SMi's 9th Annual Conference: Biobanking 2019

SMi Group25 - 26 September 2019, London, UK.
With the estimated revenues of the global biobanking industry reaching US$ 27.54 billion in 2020, backed by an explosive CAGR of 9.5% between now and 2026. This market growth is fuelled by the increasing drive towards precision and personalised medicine and thus, quality biosamples are now in soaring demand.

Come join Biobanking 2019 in September 2019 and; thoroughly understand the latest developments in the biobanking industry; network with the industry experts and key opinion leaders; gain insight into how the biobanking industry at the forefront at driving precision medicine and enhancing research and discover 'Drone4Care', how drone delivery of biosamples can be a reality.

The event will bring together internationally recognised biorepositories, scientific pioneers from pharmaceutical companies, and academics to strengthen current knowledge in biosample management and their research applications. We will cover the most relevant hot topics including: the latest biorepository technological breakthroughs, the best practices in biobanking, shifts in the biosample regulation landscape, the international biobank societies with ESBB and ISBER, along with a whole host of successful biobanking business model structures to help reinvigorate your biobank.

Benefits of attending

  • Discover 'Drone4care' from Laurent Dollé, the innovative and daring plan to use drones for the delivery of biomaterial. Additionally, he will be detailing the new promising technology of Tissue Microarray, a bioprocessing technology that can reduced the number of needed biosamples for research from 200 down to 1
  • Hear from UK Biobank on the continual impact of GDPR on the biobanking landscape
  • Learn about a diverse range of the most successful biobanking business models from real case studies
  • Gain insight from the global biobank collaboration societies of ESBB and ISBER, see how you can place your biobank on the international stage

For further information and to register, please visit:
http://www.biobanking-event.com/wpnwl

Early bird rates

  • Book by 30th April and save £400
  • Book by 31st May and save £300
  • Book by the 28th June and save £200

Plus, two interactive half day pre-conference workshops:

Workshop A: Reinvigorate your through data quality enhancement and Financial and Economic tools
Workshop Leader:Laurent Dollé, Managing Director, BWB (BiothèqueWallonieBruxelles)
8:30 - 12:30

Workshop B: The Organic Development of a Sustainable Academic Biobank
Workshop Leader:Mary-Beth Joshi, Director, Biobank & translational Research Core, Duke University Medical Centre
1:30 - 5:30

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...